On the public citation graph

Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure–Activity Relationships, and Inhibition of in Vivo T Cell Activation

0 signed · 83 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/j.1460-2075.1993.tb05812.xopenalex-snapshot
A dominant‐negative transgene defines a role for p56lck in thymopoiesis.
inferredcites →https://doi.org/10.1006/abbi.1999.1099openalex-snapshot
Inhibition of p56lckTyrosine Kinase by Isothiazolones
inferredcites →https://doi.org/10.1007/s00441-003-0749-6openalex-snapshot
Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis
inferredcites →https://doi.org/10.1016/0092-8674(92)90428-fopenalex-snapshot
Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor
inferredcites →https://doi.org/10.1016/0092-8674(95)90171-xopenalex-snapshot
Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease
inferredcites →https://doi.org/10.1016/1074-7613(95)90126-4openalex-snapshot
Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice
inferredcites →https://doi.org/10.1016/j.bbapap.2003.11.010openalex-snapshot
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
inferredcites →https://doi.org/10.1016/j.bmcl.2004.03.111openalex-snapshot
SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity
inferredcites →https://doi.org/10.1016/j.bmcl.2004.09.093openalex-snapshot
Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56Lck inhibitors
inferredcites →https://doi.org/10.1016/j.bmcl.2005.09.039openalex-snapshot
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection
inferredcites →https://doi.org/10.1016/j.bmcl.2005.11.053openalex-snapshot
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors
inferredcites →https://doi.org/10.1016/j.bmcl.2006.04.072openalex-snapshot
Development of N-4,6-pyrimidine-N-alkyl-N′-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase
inferredcites →https://doi.org/10.1016/j.bmcl.2006.12.035openalex-snapshot
Discovery of thienopyridines as Src-family selective Lck inhibitors
inferredcites →https://doi.org/10.1016/j.bmcl.2007.01.057openalex-snapshot
Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: Development of an expedient and divergent synthetic route and preliminary SAR
inferredcites →https://doi.org/10.1016/j.bmcl.2007.04.029openalex-snapshot
N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics
inferredcites →https://doi.org/10.1016/j.chembiol.2006.05.015openalex-snapshot
A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors
inferredcites →https://doi.org/10.1016/j.ejca.2006.09.015openalex-snapshot
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
inferredcites →https://doi.org/10.1016/j.intimp.2004.11.012openalex-snapshot
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases
inferredcites →https://doi.org/10.1016/j.it.2003.08.003openalex-snapshot
T-cell receptor signal transmission: who gives an ITAM?
inferredcites →https://doi.org/10.1016/j.it.2006.10.004openalex-snapshot
Angiopoietins: a link between angiogenesis and inflammation
inferredcites →https://doi.org/10.1016/s0041-1345(02)02909-3openalex-snapshot
A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
inferredcites →https://doi.org/10.1016/s0092-8674(02)00741-9openalex-snapshot
The Conformational Plasticity of Protein Kinases
inferredcites →https://doi.org/10.1016/s0092-8674(04)00215-6openalex-snapshot
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
inferredcites →https://doi.org/10.1016/s0952-7915(03)00039-6openalex-snapshot
Natural killer cell receptor signaling
inferredcites →https://doi.org/10.1016/s0955-0674(97)80064-6openalex-snapshot
T cell antigen receptor signal transduction
inferredcites →https://doi.org/10.1016/s0960-894x(00)00441-8openalex-snapshot
Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I
inferredcites →https://doi.org/10.1016/s0960-894x(02)00196-8openalex-snapshot
Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck — a selectivity insight
inferredcites →https://doi.org/10.1016/s0960-894x(02)00677-7openalex-snapshot
Synthesis and SAR of novel imidazoquinoxaline-Based Lck inhibitors: improvement of cell potency
inferredcites →https://doi.org/10.1016/s0960-894x(03)00511-0openalex-snapshot
Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors
inferredcites →https://doi.org/10.1016/s0969-2126(99)80086-0openalex-snapshot
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors
inferredcites →https://doi.org/10.1016/s1074-7613(00)80498-7openalex-snapshot
Fyn Can Partially Substitute for Lck in T Lymphocyte Development
inferredcites →https://doi.org/10.1021/jm020057ropenalex-snapshot
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
inferredcites →https://doi.org/10.1021/jm020113oopenalex-snapshot
Discovery of 2-Phenylamino-imidazo[4,5- h ]isoquinolin-9-ones: A New Class of Inhibitors of Lck Kinase
inferredcites →https://doi.org/10.1021/jm020446lopenalex-snapshot
Optimization of 2-Phenylaminoimidazo[4,5-h]isoquinolin-9-ones: Orally Active Inhibitors of lck Kinase
inferredcites →https://doi.org/10.1021/jm030217eopenalex-snapshot
Imidazoquinoxaline Src-Family Kinase p56Lck Inhibitors: SAR, QSAR, and the Discovery of (S)-N-(2-Chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a Potent and Orally Active Inhibitor with Excellent in Vivo Antiinflammatory Activity
inferredcites →https://doi.org/10.1021/jm0503594openalex-snapshot
5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase
inferredcites →https://doi.org/10.1021/jm060435iopenalex-snapshot
Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck: Synthesis, SAR, and in Vivo Antiinflammatory Activity
inferredcites →https://doi.org/10.1021/jm0605482openalex-snapshot
Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
inferredcites →https://doi.org/10.1021/jm701095mopenalex-snapshot
Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity
inferredcites →https://doi.org/10.1021/jm990499bopenalex-snapshot
2-Alkynyl-8-aryl-9-methyladenines as Novel Adenosine Receptor Antagonists: Their Synthesis and Structure−Activity Relationships toward Hepatic Glucose Production Induced via Agonism of the A2BReceptor
inferredcites →https://doi.org/10.1021/op0501601openalex-snapshot
The Synthesis of a Novel Inhibitor of B-Raf Kinase
inferredcites →https://doi.org/10.1038/357161a0openalex-snapshot
Profound block in thymocyte development in mice lacking p56lck
inferredcites →https://doi.org/10.1038/nchembio799openalex-snapshot
Rational design of inhibitors that bind to inactive kinase conformations
inferredcites →https://doi.org/10.1038/sj.onc.1208074openalex-snapshot
Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation
inferredcites →https://doi.org/10.1067/mai.2002.124259openalex-snapshot
T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse
inferredcites →https://doi.org/10.1074/jbc.271.2.695openalex-snapshot
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
inferredcites →https://doi.org/10.1074/jbc.m403319200openalex-snapshot
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
inferredcites →https://doi.org/10.1093/intimm/12.4.449openalex-snapshot
Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia
inferredcites →https://doi.org/10.1101/gad.10.15.1845openalex-snapshot
Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories.
inferredcites →https://doi.org/10.1124/jpet.105.089169openalex-snapshot
A-770041, a Novel and Selective Small-Molecule Inhibitor of Lck, Prevents Heart Allograft Rejection
inferredcites →https://doi.org/10.1126/science.289.5486.1938openalex-snapshot
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
inferredcites →https://doi.org/10.1146/annurev.immunol.15.1.371openalex-snapshot
LEUKOCYTE PROTEIN TYROSINE KINASES:Potential Targets for Drug Discovery
inferredcites →https://doi.org/10.1158/0008-5472.can-05-4187openalex-snapshot
The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
inferredcites →https://doi.org/10.1172/jci3205openalex-snapshot
Defective expression of p56lck in an infant with severe combined immunodeficiency.
inferredcites →https://doi.org/10.1179/joc.2004.16.supplement-1.59openalex-snapshot
Vascular Endothelial Growth Factor (VEGF) Inhibition by Small Molecules
inferredcites →https://doi.org/10.2174/0929867043455729openalex-snapshot
Property-Based Design of KDR Kinase Inhibitors
inferredcites →https://doi.org/10.2174/0929867043455792openalex-snapshot
Recent Kinase and Kinase Inhibitor X-ray Structures: Mechanisms of Inhibition and Selectivity Insights
inferredcites →https://doi.org/10.2174/187152307779939732openalex-snapshot
Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
inferredcites →https://doi.org/10.2741/1629openalex-snapshot
Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. current status and future perspective
inferredcites →https://doi.org/10.4049/jimmunol.142.7.2430openalex-snapshot
Lymphocyte activation provokes modification of a lymphocyte-specific protein tyrosine kinase (p56lck).
inferredcites →https://doi.org/10.4049/jimmunol.169.6.2997openalex-snapshot
TCR Signals Mediated by Src Family Kinases Are Essential for the Survival of Naive T Cells

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4679553openalex-extracted
inferred← citeshttps://doi.org/10.1002/ardp.201700369openalex-snapshot
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
inferred← citeshttps://doi.org/10.1002/cmdc.201800398openalex-snapshot
NVP‐BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family
inferred← citeshttps://doi.org/10.1002/med.21795openalex-snapshot
1,3‐Diazepine: A privileged scaffold in medicinal chemistry
inferred← citeshttps://doi.org/10.1007/s10593-009-0368-6openalex-snapshot
Synthesis of 3-(3-piperidyl)-isoquinoline and 3-(4-piperidyl)-isoquinoline
inferred← citeshttps://doi.org/10.1016/j.bmcl.2009.11.013openalex-snapshot
Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR
inferred← citeshttps://doi.org/10.1016/j.bmcl.2009.11.014openalex-snapshot
Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.129047openalex-snapshot
Identification of potent and selective inhibitors of PKR via virtual screening and traditional design
inferred← citeshttps://doi.org/10.1016/j.catcom.2019.105838openalex-snapshot
The synthesis of symmetrical 3,3-Disubstituted oxindoles by phosphine-catalyzed γ/γ-addition of oxindoles with allenoates
inferred← citeshttps://doi.org/10.1016/j.cclet.2016.01.041openalex-snapshot
Design, synthesis and immunomodulating activity of C - pseudo nucleosides containing thiazolidin-4-one and phenyl connected by acetamide bond
inferred← citeshttps://doi.org/10.1016/j.ejmech.2017.10.003openalex-snapshot
Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115475openalex-snapshot
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
inferred← citeshttps://doi.org/10.1016/j.tetlet.2024.154940openalex-snapshot
Synthesis and biological characterisation of a des-aza-dasatinib tool compound
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c01756openalex-snapshot
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor
inferred← citeshttps://doi.org/10.1021/jm4017762openalex-snapshot
Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity
inferred← citeshttps://doi.org/10.1134/s1070428015010182openalex-snapshot
Synthesis of N-aryl benzamides containing pharmacophoric tyrosine kinase inhibitor fragments
inferred← citeshttps://doi.org/10.1134/s1070428016020019openalex-snapshot
Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity
inferred← citeshttps://doi.org/10.1517/13543776.2010.517749openalex-snapshot
Update on lymphocyte specific kinase inhibitors: a patent survey
inferred← citeshttps://doi.org/10.2174/092986711796150531openalex-snapshot
Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
inferred← citeshttps://doi.org/10.4155/fmc.12.121openalex-snapshot
Development And Strategies Of VEGFR-2/KDR Inhibitors
inferred← citeshttps://doi.org/10.4155/ppa-2016-0037openalex-snapshot
Patent Highlights August–September 2016
inferred← citeshttps://doi.org/10.5935/1984-6835.20100007openalex-snapshot
Protein tyrosine kinases: challenges in the development of drugs aimed at cancer therapy
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.